Skip to main content
. Author manuscript; available in PMC: 2020 Apr 21.
Published in final edited form as: Cell Rep. 2019 May 21;27(8):2370–2384.e6. doi: 10.1016/j.celrep.2019.04.086

Figure 2. βHIF-1α Mice Develop T1D When Exposed to CVB1.

Figure 2.

(A) Kaplan-Meier plot of diabetes-free survival in mice infected with CVB1. *p < 0.05 overall.

(B) Weight of mice post-CVB1 infection. ****p < 0.0001, ANOVA.

(C) Insulin and H&E pancreatic sections at sacrifice after CVB1 infection. Scale bar, 200 μm.

(D) β cell mass in FC (black bars) and in non-diabetic (gray bars) and diabetic (white bars) βHIF-1α mice (n = 8, 5, and 4 per group, respectively) at the end of the study post-CVB1 infection. **p < 0.01 versus FC mice; ###p < 0.001 versus non-diabetic βHIF-1α mice.

(E) Serum insulin in FC (black bars) and in non-diabetic (gray bars) and diabetic (white bars) βHIF-1α mice (n = 8, 5, and 4 per group, respectively) at the end of the study. *p < 0.05 versus FC mice.

(F) Kaplan-Meier plots for diabetes-free survival in NOD-SCID recipients that were given splenocytes from CVB1-infected FC (black squares, dashed line) or βHIF-1α mice (white circles, solid line). n = 10–15 recipients per group. ****p < 0.0001.

Data are means ± SEMs.